Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLR1A | O95602 | 19/20 | 1.00 |
| ▸ | ECE1 | P42892 | 1/20 | 1.00 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17099685 | 0.94 | POLR1A (1.00) | POLR1AECE1MUS81KDM4EMEN1 | |
| SCHEMBL17099690 | 0.93 | POLR1A (1.00) | POLR1AECE1MUS81KDM4EMEN1 | |
| SCHEMBL17099653 | 0.90 | POLR1A (1.00) | POLR1AECE1MUS81KDM4EMEN1 | |
| SCHEMBL25970712 | 0.90 | POLR1A (0.81) | POLR1AECE1MUS81KDM4EMEN1 | |
| SCHEMBL17099661 | 0.89 | POLR1A (1.00) | POLR1AECE1MUS81KDM4EMEN1 | |
| SCHEMBL17117507 | 0.89 | POLR1A (1.00) | POLR1AECE1MUS81KDM4EMEN1 | |
| SCHEMBL20003190 | 0.89 | POLR1A (0.80) | POLR1AECE1MUS81KDM4EMEN1 | |
| SCHEMBL13984171 | 0.88 | POLR1A (0.78) | POLR1AECE1MUS81KDM4EMEN1 | |
| SCHEMBL25357762 | 0.87 | POLR1A (0.78) | POLR1AECE1MUS81KDM4EMEN1 | |
| Hydrogen Sulfide SCHEMBL23007616 | 0.87 | POLR1A (0.77) | POLR1AECE1MUS81KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119015288-A | Application of BMH-21 in preparation of antihypertensive drugs | 山东大学齐鲁医院 | 2024-11-26 | — | — | CN | claimed |
| CN-116942834-A | Antitumor drug comprising nucleolus stress inducer | 新乡医学院 | 2023-10-27 | — | — | CN | claimed |
| US-20230241153-A1 | METHODS AND COMPOSITIONS FOR UPREGULATING RNA INTERFERENCE AND ENHANCING GENE SILENCING | GOWEY RESEARCH GROUP, PLLC | 2023-08-03 | — | — | US | claimed |
| US-20230183705-A1 | PRODUCTS FOR SUPPRESSING OR REDUCING THE EXPRESSION OR ACTIVITY OF A SNORNA AND USES THEREOF IN THE TREATMENT OF CANCER | NINOVAX (FR) | 2023-06-15 | — | — | US | claimed |
| US-20230160018-A1 | CRYBETAB2 PREDICTS POOR BREAST CANCER OUTCOME AND SENSITIZES TUMORS TO NUCLEOLIN AND CDK INHIBITION | UNITED STATES GOVERNMENT | 2023-05-25 | — | — | US | claimed |
| EP-4135850-A1 | CRY?B2 PREDICTS POOR BREAST CANCER OUTCOME AND SENSITIZES TUMORS TO NUCLEOLIN AND CDK INHIBITION | The Johns Hopkins University (US) | 2023-02-22 | — | — | EP | claimed |
| EP-4114944-A1 | PRODUCTS FOR SUPPRESSING OR REDUCING THE EXPRESSION OR ACTIVITY OF A SNORNA AND USES THEREOF IN THE TREATMENT OF CANCER | NINOVAX (FR) | 2023-01-11 | — | — | EP | claimed |
| CN-115261408-A | Screening method and application of small molecule compound for targeted inhibition of RNA polymerase I | 杭州圣域生物医药科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-113717922-B | Kit containing transcription inhibitor and suitable for separating arabidopsis thaliana leaf tissue protoplast and application thereof | 上海欧易生物医学科技有限公司 | 2022-10-25 | — | — | CN | claimed |
| US-20260071188-A1 | METHODS OF INDUCING CELLULAR QUIESCENCE | UNIV CALIFORNIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-12570762-B2 | Conjugate or fusion protein for cancer therapy | Beijing Neoletix Biological Technology Co., Ltd. (CN) | 2026-03-10 | — | — | US | disclosed |
| CN-120041444-A | BRIX1 inhibitors and their use in anti-tumour | 新乡医学院 | 2025-05-27 | — | — | CN | disclosed |
| US-12303508-B2 | Combinatory treatment strategies of cancer based on RNA polymerase I inhibition | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2025085596-A1 | HIGH-THROUGHPUT METHODS TO IDENTIFY AND CLASSIFY MODULATORS OF NUCLEOLAR MORPHOLOGY AND FUNCTION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20140155432-A1 | ACTIVATORS AND THERAPEUTIC APPLICATIONS THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-06-05 | — | — | US | disclosed |
| US-8680107-B2 | Activators and therapeutic applications thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680107-B2 | Activators and therapeutic applications thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-03-25 | — | — | US | disclosed |
| US-20100179155-A1 | ACTIVATORS AND THERAPEUTIC APPLICATIONS THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2010-07-15 | — | — | US | disclosed |
| US-20100179155-A1 | ACTIVATORS AND THERAPEUTIC APPLICATIONS THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2010-07-15 | — | — | US | disclosed |
| WO-2008155468-A1 | ACTIVATORS AND THERAPEUTIC APPLICATIONS THEREOF | LAIHO MARIKKI (FI) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179155-A1 | ACTIVATORS AND THERAPEUTIC APPLICATIONS THEREOF | TP53, TP53BP1, DDIT3 | POLR1A 243/4885ECE1 3324/4885MUS81 1190/4885 |
| US-12303508-B2 | Combinatory treatment strategies of cancer based on RNA polymerase I inhibition | ACAT1, PARP1, POLRMT | POLR1A 7/4885ECE1 2998/4885MUS81 2784/4885 |
| US-12570762-B2 | Conjugate or fusion protein for cancer therapy | TNFSF11, TNFRSF9, CD40 | POLR1A 3771/4885ECE1 3504/4885MUS81 2716/4885 |
| US-20260071188-A1 | METHODS OF INDUCING CELLULAR QUIESCENCE | LYAR, MRTO4, RPL34 | POLR1A 463/4885ECE1 4703/4885MUS81 1874/4885 |
| US-20140155432-A1 | ACTIVATORS AND THERAPEUTIC APPLICATIONS THEREOF | TP53, TP53BP1, DDIT3 | POLR1A 243/4885ECE1 3324/4885MUS81 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.